1.
Rahim N. Bispecific CAR-T vs. BCMA-Specific CAR-T: Advancing Treatment for Relapsed/Refractory Multiple Myeloma. HSET [Internet]. 2025 Sept. 5 [cited 2026 Nov. 20];153:42-7. Available from: https://hsetarchive.drpconf.org/index.php/ojs/article/view/1041